A
Alkeus Pharmaceuticals
Biotech & Life Sciences · Boston, United States · Founded 2011
Alkeus Pharmaceuticals: Developing Treatments for Dry-AMD & Stargardt disease MoreLess
Alkeus Pharmaceuticals is a biotech startup that operates in the healthcare sector, specifically focusing on the development of treatments for genetic eye diseases. The company's primary product is ALK-001, a breakthrough therapy designed to treat Stargardt disease, a common genetic cause of blindness in children and young adults. Currently, there is no treatment for this disease, which affects over 30,000 people in the United States alone.
Stargardt disease is caused by defects in the ABCA4 gene, which results in the accumulation of toxic by-products in the eye, leading to progressive vision loss. Alkeus's ALK-001 is a modified version of vitamin A, designed to perform all the functions of vitamin A needed for sight, but without the tendency to form these toxic by-products.
The company's business model is based on the research, development, and eventual sale of this breakthrough therapy. They make money by developing and patenting their unique treatments, and then selling them to healthcare providers and patients. Their primary market is individuals suffering from Stargardt disease, but their research could potentially be applicable to other genetic eye diseases as well.
Keywords: Biotech, Healthcare, Genetic Eye Diseases, Stargardt Disease, ABCA4 Gene, Breakthrough Therapy, ALK-001, Vitamin A, Research and Development, Patent.
Company overview
Alkeus Pharmaceuticals company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2011
- Headquarters
- Boston, United States
- Employees
- 55
- Open positions
- None listed
- Dealroom signal
- 27.5
Valuation & funding
Alkeus Pharmaceuticals funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2023 | $150M | $600M | Wellington Management · TCGX · Sofinnova Investments · Bain Capital Life Sciences | ↗ |
| GRANTOther financing | Oct 2011 | $100K | — | MassChallenge | — |
| SPINOUTOther financing | Jan 2011 | $0 | — | Columbia University | — |
Growth signals
Alkeus Pharmaceuticals website traffic
Latest recorded traffic for Alkeus Pharmaceuticals is 360 monthly website visits, down 60.4% over the last three months. Alkeus Pharmaceuticals's team declined 21.4% over the past year.
Comparisons
Alkeus Pharmaceuticals compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Alkeus Pharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Alkeus Pharmaceuticals has talent and traffic
team presence
In the news
Latest news about Alkeus Pharmaceuticals
Recent press, funding announcements, and product moves mentioning Alkeus Pharmaceuticals — open to read from the original sources.
Market sentiment
What the market is saying about Alkeus Pharmaceuticals
An AI-synthesized read of the highest-engagement posts about Alkeus Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alkeus Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.